Filed with the SEC on · accession 0001828316-26-000051
PHAR filed a 6-K (foreign company report) with the SEC on Nov 6, 2026. The U.K. MHRA approved an extension of the marketing authorization for Pharming's Joenja (leniolisib) to include children aged 4 to 11 weighing at least 27 kg with APDS, making it the first treatment specifically approved for children with APDS in the U.K.
The U.K. MHRA approved an extension of the marketing authorization for Pharming's Joenja (leniolisib) to include children aged 4 to 11 weighing at least 27 kg with APDS, making it the first treatment specifically approved for children with APDS in the U.K. The drug is expected to become available to these patients in February 2027.
✦ Ask GOAX AI about this filing — what it means for PHAR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PHAR?
Click herePHAR filed a 6-K (Fda approval). The U.K. MHRA approved an extension of the marketing authorization for Pharming's Joenja (leniolisib) to include children aged 4 to 11 weighing at least 27 kg with APDS, making it the first treatment specifically approved for children with APDS in the U.K. The drug is expected to become available to these patients in February 2027.
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Get alerts when PHAR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days